Overview

• The oPool+ display platform rapidly synthesizes and assays large sets of natively paired antibodies in parallel.
• In a proof-of-concept, researchers built about 300 antibody variants and tested them against multiple influenza hemagglutinin variants.
• The team reported more than 5,000 binding tests completed in three to five days of hands-on work, enabling quick specificity profiling.
• Materials costs fell by an estimated 80–90% compared with traditional one-at-a-time antibody workflows.
• Findings included shared binding features across antibodies from different people, with plans to scale to thousands of antibodies, broaden to other pathogens and cancer, and validate AI prediction models.